keyword
MENU ▼
Read by QxMD icon Read
search

breast cancer, metastatic, prognostic markers

keyword
https://www.readbyqxmd.com/read/29755127/a-novel-long-non-coding-rna-linc-znf469-3-promotes-lung-metastasis-through-mir-574-5p-zeb1-axis-in-triple-negative-breast-cancer
#1
Po-Shun Wang, Cheng-Han Chou, Cheng-Han Lin, Yun-Chin Yao, Hui-Chuan Cheng, Hao-Yi Li, Yu-Chung Chuang, Chia-Ning Yang, Luo-Ping Ger, Yu-Chia Chen, Forn-Chia Lin, Tang-Long Shen, Michael Hsiao, Pei-Jung Lu
Triple-negative breast cancer (TNBC) patients usually lead to poor prognosis and survival because of metastasis. The major sites for TNBC metastasis include the lungs, brain, liver, and bone. Long non-coding RNAs (lncRNAs) are non-protein-coding transcripts longer than 200 nucleotides and have been reported as important regulators in BC metastasis. However, the underlying mechanisms for lncRNAs regulating TNBC metastasis are not fully understood. Here we found that linc-ZNF469-3 was highly expressed in lung-metastatic LM2-4175 TNBC cells and overexpression of linc-ZNF469-3 enhanced invasion ability and stemness properties in vitro and lung metastasis in vivo...
May 14, 2018: Oncogene
https://www.readbyqxmd.com/read/29738261/the-significance-of-the-stromal-response-in-breast-cancer-an-immunohistochemical-study-of-myofibroblasts-in-primary-and-metastatic-breast-cancer
#2
Alale Roozdar, Malcolm M Hayes, Bahram Pourseyedei, Hamid Zeinalinejad, Manzumeh Shamsi Meymandi, Bahram Dabiri, Shahriar Dabiri
BACKGROUND: Gene expression profiling of breast cancer has demonstrated the importance of stromal response in determining the prognosis of invasive breast cancer. The host response to breast cancer is of increasing interest to pathologists and may be a future focus for novel pharmacological treatments. METHODS: This study describes the pattern of distribution of stromal myofibroblasts using immunostains for CD10 and smooth muscle actin (SMA) in 50 primary breast cancers and their matched nodal metastases (68...
May 1, 2018: Archives of Iranian Medicine
https://www.readbyqxmd.com/read/29713057/intermittent-hypoxia-induces-a-metastatic-phenotype-in-breast-cancer
#3
Anna Chen, Jaclyn Sceneay, Nathan Gödde, Tanja Kinwel, Sunyoung Ham, Erik W Thompson, Patrick O Humbert, Andreas Möller
Hypoxia arises frequently in solid tumors and is a poor prognostic factor as it promotes tumor cell proliferation, invasion, angiogenesis, therapy resistance, and metastasis. Notably, there are two described forms of hypoxia present in a growing tumor: chronic hypoxia, caused by abnormal tumor vasculature, and intermittent hypoxia, caused by transient perfusion facilitated by tumor-supplying blood vessels. Here, we demonstrate that intermittent hypoxia, but not chronic hypoxia, endows breast cancer cells with greater metastatic potential...
May 1, 2018: Oncogene
https://www.readbyqxmd.com/read/29675680/a-randomized-double-blind-phase-2-study-of-ruxolitinib-or-placebo-in-combination-with-capecitabine-in-patients-with-advanced-her2-negative-breast-cancer-and-elevated-c-reactive-protein-a-marker-of-systemic-inflammation
#4
Joyce O'Shaughnessy, Angela DeMichele, Cynthia X Ma, Paul Richards, Denise A Yardley, Gail Shaw Wright, Kevin Kalinsky, Ronald Steis, Sami Diab, Gerard Kennealey, Ryan Geschwindt, Wei Jiang, Hope S Rugo
PURPOSE: The Janus-associated kinase (JAK)/signal transducer and activator of transcription pathway is a key regulator of inflammatory signaling, associated with tumorigenesis, cell survival, and progression. This randomized phase 2 trial evaluated the efficacy and safety of the addition of ruxolitinib, a JAK1/JAK2 inhibitor, to capecitabine in patients with HER2-negative advanced breast cancer and high systemic inflammation (modified Glasgow Prognostic Score [mGPS] ≥ 1). METHODS: Patients with ≤ 2 prior chemotherapy regimens for advanced or metastatic disease or hormone receptor-positive patients with disease progression on prior hormonal therapies were randomized 1:1 to 21-day cycles of ruxolitinib (n = 76) or placebo (n = 73) plus capecitabine...
April 19, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29662653/plasma-thymidine-kinase-1-activity-predicts-outcome-in-patients-with-hormone-receptor-positive-and-her2-negative-metastatic-breast-cancer-treated-with-endocrine-therapy
#5
Martina Bonechi, Francesca Galardi, Chiara Biagioni, Francesca De Luca, Mattias Bergqvist, Magnus Neumüller, Cristina Guarducci, Giulia Boccalini, Stefano Gabellini, Ilenia Migliaccio, Angelo Di Leo, Marta Pestrin, Luca Malorni
The aim of this study was to investigate if thymidine kinase-1 (TK1), a well-known proliferation marker, could represent a valid circulating biomarker to identify hormone receptor positive (HR+)/HER2 negative (HER2neg) metastatic breast cancer (MBC) patients most likely to benefit from endocrine therapy (ET). We used the DiviTum™ assay to analyze TK1 activity in cell lysates of three HR+/HER2neg BC cell lines and in plasma of 31 HR+/HER2neg MBC patients receiving ET. Blood samples were collected at treatment initiation, after one month and at disease progression...
March 27, 2018: Oncotarget
https://www.readbyqxmd.com/read/29593307/morphology-of-immunomodulation-in-breast-cancer-tumor-draining-lymph-nodes-depends-on-stage-and-intrinsic-subtype
#6
Maximilian Seidl, Moritz Bader, Astrid Vaihinger, Ulrich F Wellner, Rumyana Todorova, Bettina Herde, Klaudia Schrenk, Jochen Maurer, Oliver Schilling, Thalia Erbes, Paul Fisch, Jens Pfeiffer, Linda Hoffmann, Kai Franke, Martin Werner, Peter Bronsert
Cancer research of immune-modulating mechanisms mainly addresses the role of tumor-infiltrating immune cells. Mechanisms modulating the adaptive immune system at the primary activation site - the draining lymph node (LN) - are less investigated. Here we present tumor-caused histomorphological changes in tumor draining LNs of breast cancer patients, dependent on the localization (sentinel LN vs. non-sentinel LN), the tumor size, the intrinsic subtype and nodal metastatic status. The quantitative morphological study was conducted in breast cancer patients with at least one sentinel LN and no neoadjuvant therapy...
March 28, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29539586/nephronectin-is-correlated-with-poor-prognosis-in-breast-cancer-and-promotes-metastasis-via-its-integrin-binding-motifs
#7
Tonje S Steigedal, Jimita Toraskar, Richard P Redvers, Marit Valla, Synnøve N Magnussen, Anna M Bofin, Signe Opdahl, Steinar Lundgren, Bedrich L Eckhardt, John M Lamar, Judy Doherty, Richard O Hynes, Robin L Anderson, Gunbjørg Svineng
Most cancer patients with solid tumors who succumb to their illness die of metastatic disease. While early detection and improved treatment have led to reduced mortality, even for those with metastatic cancer, some patients still respond poorly to treatment. Understanding the mechanisms of metastasis is important to improve prognostication, to stratify patients for treatment, and to identify new targets for therapy. We have shown previously that expression of nephronectin (NPNT) is correlated with metastatic propensity in breast cancer cell lines...
April 2018: Neoplasia: An International Journal for Oncology Research
https://www.readbyqxmd.com/read/29535130/p95her2-methionine-611-carboxy-terminal-fragment-is-predictive-of-trastuzumab-adjuvant-treatment-benefit-in-the-finher-trial
#8
Jeff Sperinde, Weidong Huang, Aki Vehtari, Ahmed Chenna, Pirkko-Liisa Kellokumpu-Lehtinen, John Winslow, Petri Bono, Yolanda S Lie, Christos J Petropoulos, Jodi Weidler, Heikki Joensuu
Purpose: Expression of p95HER2 (p95), a truncated form of the HER2 receptor, which lacks the trastuzumab binding site but retains kinase activity, has been reported as a prognostic biomarker for poor outcomes in patients with trastuzumab-treated HER2-positive metastatic breast cancer. The impact of p95 expression on trastuzumab treatment efficacy in early HER2-positive breast cancer is less clear. In the current study, p95 was tested as a predictive marker of trastuzumab treatment benefit in the HER2-positive subset of the FinHer adjuvant phase III trial...
March 13, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29515971/the-expression-and-prognostic-impact-of-immune-cytolytic-activity-related-markers-in-human-malignancies-a-comprehensive-meta-analysis
#9
Constantinos Roufas, Dimitrios Chasiotis, Anestis Makris, Christodoulos Efstathiades, Christos Dimopoulos, Apostolos Zaravinos
Background: Recently, immune-checkpoint blockade has shown striking clinical results in different cancer patients. However, a significant inter-individual and inter-tumor variability exists among different cancers. The expression of the toxins granzyme A (GZMA) and perforin 1 (PRF1), secreted by effector cytotoxic T cells and natural killer (NK) cells, were recently used as a denominator of the intratumoral immune cytolytic activity (CYT). These levels are significantly elevated upon CD8+ T-cell activation as well as during a productive clinical response against immune-checkpoint blockade therapies...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29416769/roles-of-malat1-in-development-and-migration-of-triple-negative-and-her-2-positive-breast-cancer
#10
Zhang Xiping, Chen Bo, Yang Shifeng, Yu Feijiang, Yang Hongjian, Cheng Qihui, Tang Binbin
Background: As a type of new targets for prognosis of malignancies, long non-coding RNA MALAT1 (metastasis-associated lung adenocarcinoma transcription 1) is associated with proliferation and metastatic abilities of several malignancies. However, its relations to development and migration of triple negative and human epidermal growth factor receptor 2 (Her-2) positive breast cancers haven't been reported. Objectives: In this paper, we aimed to discuss how MALAT1 is connected with and affects proliferation and invasion abilities of cells in Her-2 positive and triple-negative breast cancers (TNBC)...
January 5, 2018: Oncotarget
https://www.readbyqxmd.com/read/29413654/ancillary-prognostic-and-predictive-testing-in-breast-cancer-focus-on-discordant-unusual-and-borderline-results
#11
REVIEW
Kimberly H Allison
Ancillary testing in breast cancer has become standard of care to determine what therapies may be most effective for individual patients with breast cancer. Single-marker tests are required on all newly diagnosed and newly metastatic breast cancers. Markers of proliferation are also used, and include both single-marker tests like Ki67 as well as panel-based gene expression tests, which have made more recent contributions to prognostic and predictive testing in breast cancers. This review focuses on pathologist interpretation of these ancillary test results, with a focus on expected versus unexpected results and troubleshooting borderline, unusual, or discordant results...
March 2018: Surgical Pathology Clinics
https://www.readbyqxmd.com/read/29409452/whole-blood-micrornas-as-potential-biomarkers-in-post-operative-early-breast-cancer-patients
#12
Marianna Alunni-Fabbroni, Leonie Majunke, Elisabeth K Trapp, Marie Tzschaschel, Sven Mahner, Peter A Fasching, Tanja Fehm, Andreas Schneeweiss, Thomas Beck, Ralf Lorenz, Thomas W P Friedl, Wolfgang Janni, Brigitte Rack
BACKGROUND: microRNAs (miRNAs) are considered promising cancer biomarkers, showing high reliability, sensitivity and stability. Our study aimed to identify associations between whole blood miRNA profiles, presence of circulating tumor cells (CTCs) and clinical outcome in post-operative early breast cancer patients (EBC) to assess the utility of miRNAs as prognostic markers in this setting. METHOD: A total of 48 post-operative patients, recruited in frame of the SUCCESS A trial, were included in this retrospective study and tested with a panel of 8 miRNAs (miR-10b, -19a, - 21, - 22, -20a, - 127, - 155, -200b)...
February 6, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29386247/the-role-of-the-ar-er-ratio-in-er-positive-breast-cancer-patients
#13
Nelson Rangel, Milena Rondon-Lagos, Laura Annaratone, Simona Osella-Abate, Jasna Metovic, Maria Piera Mano, Luca Bertero, Paola Cassoni, Anna Sapino, Isabella Castellano
The significance of androgen receptor (AR) in breast cancer (BC) management is not fully defined, and it is still ambiguous how the level of AR expression influences oestrogen receptor-positive (ER+) tumours. The aim of the present study was to analyse the prognostic impact of AR/ER ratio, evaluated by immunohistochemistry (IHC), correlating this value with clinical, pathological and molecular characteristics. We retrospectively selected a cohort of 402 ER+BC patients. On each tumour, IHC analyses for AR, ER, PgR, HER2 and Ki67 were performed and AR+ cases were used to calculate the AR/ER value...
March 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29343249/microrna-124-inhibits-bone-metastasis-of-breast-cancer-by-repressing-interleukin-11
#14
Wei-Luo Cai, Wen-Ding Huang, Bo Li, Tian-Rui Chen, Zhen-Xi Li, Cheng-Long Zhao, Heng-Yu Li, Yan-Mei Wu, Wang-Jun Yan, Jian-Ru Xiao
BACKGROUND: Most patients with breast cancer in advanced stages of the disease suffer from bone metastases which lead to fractures and nerve compression syndromes. microRNA dysregulation is an important event in the metastases of breast cancer to bone. microRNA-124 (miR-124) has been proved to inhibit cancer progression, whereas its effect on bone metastases of breast cancer has not been reported. Therefore, this study aimed to investigate the role and underlying mechanism of miR-124 in bone metastases of breast cancer...
January 17, 2018: Molecular Cancer
https://www.readbyqxmd.com/read/29340882/circulating-small-sized-endothelial-microparticles-as-predictors-of-clinical-outcome-after-chemotherapy-for-breast-cancer-an-exploratory-analysis
#15
Elisa García Garre, Ginés Luengo Gil, Silvia Montoro García, Enrique Gonzalez Billalabeitia, Marta Zafra Poves, Elena García Martinez, Vanessa Roldán Schilling, Esther Navarro Manzano, Alejandra Ivars Rubio, Gregory Y H Lip, Francisco Ayala de la Peña
PURPOSE: Therapeutic exploitation of angiogenesis in breast cancer has been limited by the lack of reliable biomarkers. Circulating small-sized endothelial microparticles (sEMP) are likely to play a significant role as messengers of angiogenesis. Higher levels of EMP have been observed in cancer patients, but their prognostic value in breast cancer is unknown. Our aim was to determine the value of circulating sEMP as a marker of response to chemotherapy in breast cancer. METHODS: We included patients with breast cancer treated with neoadjuvant or first-line chemotherapy...
January 16, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29340881/circulating-free-dna-integrity-and-concentration-as-independent-prognostic-markers-in-metastatic-breast-cancer
#16
Jie Cheng, Tim Holland-Letz, Markus Wallwiener, Harald Surowy, Katarina Cuk, Sarah Schott, Andreas Trumpp, Klaus Pantel, Christof Sohn, Andreas Schneeweiss, Barbara Burwinkel
PURPOSE: Non-invasive blood-based molecular markers have been investigated for cancer diagnosis and prognosis. Circulating free or cell-free DNA (cfDNA) variables have been shown to be putative markers in breast cancer prognosis. METHODS: Here, we investigated the potential prognostic ability of cfDNA concentration and cfDNA integrity (cfDI) in a study cohort of 268 patients by quantitative PCR. We compared cfDNA concentration and cfDI at baseline and after one cycle of therapy in metastatic breast cancer (MBC) patients...
January 16, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29330143/breast-cancer-targeting-through-inhibition-of-the-endoplasmic-reticulum-based-apoptosis-regulator-nrh-bcl2l10
#17
Adrien Nougarede, Nikolay Popgeorgiev, Loay Kassem, Soleilmane Omarjee, Stephane Borel, Ivan Mikaelian, Jonathan Lopez, Rudy Gadet, Olivier Marcillat, Isabelle Treilleux, Bruno O Villoutreix, Ruth Rimokh, Germain Gillet
Drug resistance and metastatic relapse remain a top challenge in breast cancer treatment. In this study, we present preclinical evidence for a strategy to eradicate advanced breast cancers by targeting the BCL-2 homolog Nrh/BCL2L10, which we discovered to be overexpressed in >45% of a large cohort of breast invasive carcinomas. Nrh expression in these tumors correlated with reduced metastasis-free survival, and we determined it to be an independent marker of poor prognosis. Nrh protein localized to the endoplasmic reticulum...
March 15, 2018: Cancer Research
https://www.readbyqxmd.com/read/29158783/fascin-expression-is-inversely-correlated-with-breast-cancer-metastasis-suppressor-1-and-predicts-a-worse-survival-outcome-in-node-negative-breast-cancer-patients
#18
Hye Jin Lee, Hee Jung An, Tae Hoen Kim, Gwangil Kim, Haeyoun Kang, Jin Hyung Heo, Ah-Young Kwon, Sewha Kim
Background: Fascin is an actin-bundling protein that promotes cancer cell migration and invasion. By contrast, breast cancer metastasis suppressor 1 (BRMS1) inhibits cancer metastasis by targeting multiple steps of the metastatic cascade. We evaluated whether expression patterns of fascin and BRMS1 correlate with clinicopathological features and patient outcome. Methods: Immunohistochemistry for fascin and BRMS1 was performed using a tissue microarray constructed from 183 human breast cancer tissues. Fascin expression determined by the proportion of stained tumor cells (0: 0-5%, 1: 6-25%, 2: 26-50%, 3: 51-75%, or 4: >75%) and staining intensity (0: negative, 1: weak, 2: moderate, or 3: strong) were multiplied and defined as negative (0-3) or positive (4-12)...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/29147870/changes-in-body-composition-and-muscle-attenuation-during-taxane-based-chemotherapy-in-patients-with-metastatic-breast-cancer
#19
Hánah N Rier, Agnes Jager, Stefan Sleijfer, Joost van Rosmalen, Marc C J M Kock, Mark-David Levin
PURPOSE: Body composition parameters including low muscle mass, muscle attenuation (which reflects muscle quality) and adipose tissue measurements have emerged as prognostic factors in cancer patients. However, knowledge regarding the possibility of excessive muscle loss during specific systemic therapies is unknown. We describe the changes in body composition and muscle attenuation (MA) during taxane- and anthracycline-based regimens and its association with overall survival (OS) in metastatic breast cancer patients...
February 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29115935/microrna-expression-patterns-in-canine-mammary-cancer-show-significant-differences-between-metastatic-and-non-metastatic-tumours
#20
Malgorzata Bulkowska, Agata Rybicka, Kerem Mert Senses, Katarzyna Ulewicz, Katarzyna Witt, Joanna Szymanska, Bartlomiej Taciak, Robert Klopfleisch, Eva Hellmén, Izabella Dolka, Ali O Gure, Joanna Mucha, Mariusz Mikow, Slawomir Gizinski, Magdalena Krol
BACKGROUND: MicroRNAs may act as oncogenes or tumour suppressor genes, which make these small molecules potential diagnostic/prognostic factors and targets for anticancer therapies. Several common oncogenic microRNAs have been found for canine mammary cancer and human breast cancer. On account of this, large-scale profiling of microRNA expression in canine mammary cancer seems to be important for both dogs and humans. METHODS: Expression profiles of 317 microRNAs in 146 canine mammary tumours of different histological type, malignancy grade and clinical history (presence/absence of metastases) and in 25 control samples were evaluated...
November 7, 2017: BMC Cancer
keyword
keyword
80880
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"